ABOS

Acumen Pharmaceuticals Inc

NASDAQ

Add Alert

ABOS

Acumen Pharmaceuticals Inc

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Monksdream PremiumMember

03/24/24 4:07 PM

Post #32

ABOS 10Q due 3/26

Monksdream PremiumMember

11/12/23 11:37 AM

Post #31

ABOS new 52 week low

prof81

08/01/23 9:41 AM

Post #30

Buying pressure……

bayjammng

07/17/23 2:39 PM

Post #29

Could someone please ask the company how they compare to those in today's CNN article - thx. https://www.cnn.com/2023/07/17/health/second-alzheimers-drug-to-slow-disease-may-be-approved-this-year/index.html

bayjammng

07/17/23 2:39 PM

Post #28

Stockexpertpro Free

07/17/23 9:09 AM

Post #27

Ouch Stock Offering With Warrants

TheFinalCD PremiumMember

07/17/23 8:39 AM

Post #26

Re: #23: @tw0122 - Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human

wow went even higher

Jayzp

07/17/23 8:37 AM

Post #25

THER STOCK..WILL JUMP SAME WAY as abos, prfx

THER CANCER TESTS AND TREATMENT OPTIONS

THERALINK.COM

Going to be nasdaq merger with BACK

Stockexpertpro Free

07/17/23 8:22 AM

Post #24

ABOS Nice Watch BBIO Above 31$ on News as well

tw0122

07/17/23 4:48 AM

Post #23

Re: #22: @Invest-in-America - ABOS: Could get a little pop behind this news:

Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023

Source: GlobeNewswire Inc.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AßOs) for the treatment of Alzheimer’s disease (AD), today presented positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AßO targeting antibody therapy in early AD, at the Alzheimer’s Association International Conference (AAIC®) 2023, taking place in Amsterdam and online from July 16-20, 2023.
Topline results demonstrated that ACU193 was generally well-tolerated with a compelling overall safety profile, meeting the primary objective of this Phase 1, first-in-human, randomized, double-blind, placebo-controlled study in both single and multiple doses in 60 participants with early AD. Dose levels were 2, 10, 25 and 60 mg/kg for one to three doses administered intravenously. An analysis of change in amyloid plaque load, as measured by positron emission tomography (PET) SUVr, demonstrated a rapid, dose-related mean decrease at the higher dose levels studied (60 mg/kg every 4 weeks [Q4W] and 25 mg/kg every 2 weeks [Q2W]). This finding is comparable to mean amyloid plaque decreases of approved Aß monoclonal antibodies at similar time points in their clinical development. The overall rate of amyloid related imaging abnormalities – edema (ARIA-E) was 10.4%, which included one case of symptomatic ARIA-E (2.1%). Pharmacokinetic results in serum and cerebrospinal fluid (CSF) demonstrated statistically significant dose proportionality and support monthly dosing of ACU193. Statistically significant, dose-related central target engagement was observed as measured by ACU193-AßO complex, establishing the first target engagement assay developed that is specific to an AßO-targeting antibody. An exposure response relationship (Emax) model revealed near maximal target engagement with repeated dosing at 25 mg/kg and 60 mg/kg.

“We are very pleased to present the first clinical data from our Phase 1 INTERCEPT-AD study at AAIC. ACU193’s observed dose-related central target engagement, rapid reduction of amyloid plaque and compelling safety profile validate our confidence in ACU193’s differentiated mechanism of action: selectively targeting amyloid beta oligomers,” said Daniel O’Connell, President and Chief Executive Officer of Acumen. “We believe that the robust data package generated by this comprehensive Phase 1 study establishes ACU193’s broad therapeutic index and guides a future clinical dosing rationale. We look forward to an anticipated interaction with the FDA in the fourth quarter to inform our next phase of development for ACU193.”

ACU193 Demonstrated Rapid, Dose-Related, Statistically Significant Amyloid Plaque Reduction
Higher doses of ACU193 (60 mg/kg Q4W and 25 mg/kg Q2W) showed a statistically significant reduction in amyloid plaque load as determined by amyloid PET after 6-12 weeks (from baseline to endpoint within cohorts (p = 0.01)). This finding provides evidence that ACU193 is active in the brain.

Mean Reduction in Amyloid Plaque (Centiloids)

Invest-in-America Free

07/16/23 10:20 PM

Post #22

ABOS: Could get a little pop behind this news:
https://www.globenewswire.com/news-release/2023/07/16/2705282/0/en/Acumen-Pharmaceuticals-Presents-Positive-Topline-Results-from-First-in-Human-Phase-1-Study-of-ACU193-for-Early-Alzheimer-s-Disease-at-the-Alzheimer-s-Association-International-Conf.html

Moonboy1

12/02/22 6:21 AM

Post #21

Down over 50% from yearly highs and still dropping. Back to 3's I guess.

Moonboy1

10/27/22 6:29 PM

Post #20

One penny away haha. That's amazing. Charts never lie.

Moonboy1

10/25/22 9:27 PM

Post #19

Almost there.

Moonboy1

10/21/22 8:16 AM

Post #18

Getting close to my buy price. 6s probably today

Moonboy1

10/19/22 9:43 AM

Post #17

I'm a buyer under $7. Just going by the charts and support is at $6.50 ish range. GL.

starkd748

10/13/22 3:12 PM

Post #16

Re: #15: @Moonboy1 - I know TA. I was just pointing out

I never look at YouTube or analysts ELLIOTT WAVES and fibonanci..If the .618 holds at 7.95 would be bullish for wave 5 on the ELLIOTT WAVE either that or it goes to the fibonanci .382 level in the 6s

Moonboy1

10/13/22 8:17 AM

Post #15

Re: #13: @starkd748 - 7.95 at the .618 is a buy if

I know TA. I was just pointing out that these people were pumping it at the peak with a buy rating. That's like a you tuber telling you about a penny stock after it ran up 200% that day. The fibs havnt been very predictable lately in this bear market. But for a short term bounce maybe the .618 is a good indicator. I'm looking at the chart and there is some support at around the $7.00 level and a lot of support at the $6.50ish level. Anything under $8 does seem like a good time to start dollar cost averaging back in however in my opinion. GL. $ABOS

Moonboy1

10/13/22 8:16 AM

Post #14

Re: #13: @starkd748 - 7.95 at the .618 is a buy if

starkd748

10/13/22 1:15 AM

Post #13

Re: #12: @Moonboy1 - So how much did they pay these analysts

7.95 at the .618 is a buy if the pivot point holds we go to the 1.618 fibonanci extension...Analysts don't mean anything...Chart the fibonanci retracement...You need newbies need to understand technical analysis not reading prs lmfao...